 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin purchased 1,882 shares of the firm's stock in a transaction dated Thursday, March 28th. The shares were...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 Shares

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval...

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin bought 1,882 shares of Outlook Therapeutics stock in a transaction dated Thursday, March 28th. The stock was...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Purchases 1,882 Shares of Stock

Outlook Therapeutics files for $300M mixed securities shelf...

Outlook Therapeutics files for $300M mixed securities shelf

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Outlook Therapeutics files $300M mixed securities shelf

Outlook Therapeutics just upgraded at BTIG, here's why

Outlook Therapeutics (NASDAQ:OTLK  Free Report) had its price target increased by HC Wainwright to $30.00 in a research note released on Monday morning, Benzinga reports. HC Wainwright...

Outlook Therapeutics (NASDAQ:OTLK) Price Target Increased to $30.00 by Analysts at HC Wainwright

Outlook Therapeutics files to sell 21.43M shares of common stock for holders

This is a Bullish indicator signaling OTLK's price could rise from here. Traders may explore going long the stock or buying call options...

Outlook Therapeutics (OTLK, $8.63) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Volume (M)	271,784.00
52-Wk High	$40.60
52-Wk Low	$4.00

OTLK Outlook Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals